Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A

Hypertension. 1999 Jan;33(1 Pt 2):408-13. doi: 10.1161/01.hyp.33.1.408.

Abstract

The current study determined the contribution of protein kinase-A (PKA) and protein kinase-G (PKG) to the vasodilation elicited by the N-methylsulfonimide analog of 11,12-epoxyeicosatrienoic acid (11, 12-EET). Experiments were performed, in vitro, using the juxtamedullary nephron preparation combined with videomicroscopy. The response of afferent arterioles to the sulfonimide analog of 11, 12-EET, was determined before and after inhibition of PKA, PKG, or guanylyl cyclase. Afferent arterioles, preconstricted with 0.5 micromol/L norepinephrine, averaged 18+/-1 microm (n=25) at a renal perfusion pressure of 100 mm Hg. Superfusion with 0.01 to 100 nmol/L of the 11,12-EET analog caused a graded increase in diameter of the afferent arteriole. Vessel diameter increased by 11+/-1% and 15+/-1%, respectively, in response to 10 and 100 nmol/L of the 11,12-EET analog. The afferent arteriolar response to 10 and 100 nmol/L of the 11,12-EET analog was significantly attenuated during inhibition of PKA with 10 micromol/L H-89 (n=7) or 5 micromol/L myristolated PKI (n=6), such that afferent arteriolar diameter increased by only 5+/-2% and 2+/-1%, respectively, in response to 100 nmol/L of the 11, 12-EET analog. In contrast, the afferent arteriolar vasodilatory response to the 11,12-EET analog was unaffected by PKG or guanylyl cyclase inhibition. In the presence of 200 micromol/L histone H2B (n=5) or 10 micromol/L ODQ (n=7), the afferent arteriolar diameter increased by 16+/-3% and 12+/-2%, respectively, in response to 100 nmol/L of the 11,12-EET analog. These results demonstrate that activation of PKA is an important mechanism responsible for the afferent arteriolar vasodilation elicited by the sulfonimide analog of 11,12-EET.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / pharmacology*
  • 8-Bromo Cyclic Adenosine Monophosphate / pharmacology
  • Animals
  • Arterioles / drug effects
  • Arterioles / physiology*
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Cyclic GMP / analogs & derivatives
  • Cyclic GMP / pharmacology
  • Cyclic GMP-Dependent Protein Kinases
  • Enzyme Inhibitors / pharmacology*
  • Guanylate Cyclase / metabolism
  • Histones / pharmacology
  • In Vitro Techniques
  • Isoquinolines / pharmacology
  • Juxtaglomerular Apparatus / blood supply
  • Kidney Medulla / blood supply
  • Kinetics
  • Male
  • Microscopy, Video
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology*
  • Nephrons / blood supply
  • Norepinephrine / pharmacology
  • Oxadiazoles / pharmacology
  • Protein Kinases / metabolism
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Renal Circulation / drug effects*
  • Sulfonamides*
  • Vasodilation / drug effects*

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Enzyme Inhibitors
  • Histones
  • Isoquinolines
  • Oxadiazoles
  • Quinoxalines
  • Sulfonamides
  • 8-Bromo Cyclic Adenosine Monophosphate
  • 8-bromocyclic GMP
  • Protein Kinases
  • Cyclic AMP-Dependent Protein Kinases
  • Cyclic GMP-Dependent Protein Kinases
  • Guanylate Cyclase
  • 8,11,14-Eicosatrienoic Acid
  • Cyclic GMP
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Norepinephrine